Our nanoimmunotherapy solution

IB-001 copy (1).png

ImmunoBlue harnesses the advantages of nanomedicine and immunotherapy for treating advanced cancers. ImmunoBlue has developed a nanoparticle platform composed of an FDA-approved material, which when laser-activated to a tumor-specific immunogenic thermal dose “window” discovered by us, generates potent responses from the immune system to more effectively treat advanced cancers. These effects combine synergistically with immunotherapies (e.g. cell therapies, monoclonal antibodies, cytokines) to generate long-term survival and immunological memory in various cancer models (e.g. melanoma, neuroblastoma).